Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O0PY
|
||||
| Former ID |
DIB010195
|
||||
| Drug Name |
Pagoclone
|
||||
| Synonyms |
IP-456; RP-59037; RP-62955
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Phase 2/3 | [1] | ||
| Company |
Rhone-Poulenc SA
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H22ClN3O2
|
||||
| Canonical SMILES |
N1(C(=O)c2c(C1CC(=O)CCC(C)C)cccc2)c1nc2nc(ccc2cc1)Cl
|
||||
| CAS Number |
CAS 133737-32-3
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | GABA A receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | |||||
| GABAergic synapse | |||||
| Morphine addiction | |||||
| Nicotine addiction | |||||
| Reactome | Ligand-gated ion channel transport | ||||
| GABA A receptor activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Iron uptake and transport | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00830154) A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering. U.S. National Institutes of Health. | ||||
| REF 2 | Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.